Brief: Xortx Announces Positive Topline Results From Xrx-Oxy-101 Clinical Trial
19/01/2023 12:49
Jan 19 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX ANNOUNCES POSITIVE TOPLINE RESULTS FROM XRX-OXY-101
CLINICAL TRIAL
* XORTX THERAPEUTICS INC - RESULTS FROM STUDY SHOWED THAT
XORLOTM
WAS WELL TOLERATED ACROSS VARIOUS DOSING REGIMENS
* XORTX THERAPEUTICS INC - NO SAFETY ISSUES WERE IDENTIFIED
IN ANY
OF FOUR PARTS OF STUDY ON 88 SUBJECTS WHO RECEIVED DRUG
Source text for Eikon: ID:nGNX109M3q
Further company coverage: XRTX.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering